318 related articles for article (PubMed ID: 15449961)
1. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
Schädlich PK; Huppertz E; Brecht JG
Pharmacoeconomics; 1998 Dec; 14(6):653-69. PubMed ID: 10346417
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events.
Capri S; Perlini S
Curr Med Res Opin; 2005 Jun; 21(6):913-21. PubMed ID: 16003858
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.
Aurbach A; Russ W; Battegay E; Bucher HC; Brecht JG; Schädlich PK; Sendi P
Swiss Med Wkly; 2004 Jul; 134(27-28):399-405. PubMed ID: 15389357
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
[TBL] [Abstract][Full Text] [Related]
7. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
Grover SA; Coupal L; Lowensteyn I
Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.
Smith MG; Neville AM; Middleton JC
Intern Med J; 2003; 33(9-10):414-9. PubMed ID: 14511193
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
Björholt I; Andersson FL; Kahan T; Ostergren J
J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Malik IS; Bhatia VK; Kooner JS
Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
[TBL] [Abstract][Full Text] [Related]
11. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
Carroll CA; Coen MM; Rymer MM
Clin Ther; 2003 Apr; 25(4):1248-61. PubMed ID: 12809971
[TBL] [Abstract][Full Text] [Related]
13. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
Lamy A; Yusuf S; Pogue J; Gafni A;
Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic impact of HOPE.
Ostergren JB; Björholt I; Andersson F; Kahan T
Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.
Carroll CA; Coen MM; Piepho RW
Ann Pharmacother; 2003 Mar; 37(3):327-31. PubMed ID: 12639157
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
20. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
